Development and validation of a neutrophil extracellular traps-related gene signature for lower-grade gliomas

被引：0

作者：

Zhang, Wei ^{[1
]}

Xie, Youlong ^{[2
]}

Chen, Fengming ^{[3
]}

Xie, Biao ^{[4
]}

Yin, Zhihua ^{[1
]}

机构：

[1] Department of Epidemiology, School of Public Health, China Medical University, Liaoning Province, Shenyang

[2] Joint International Research Laboratory of Reproduction and Development of the Ministry of Education of China, School of Public Health, Chongqing Medical University, Chongqing

[3] Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomics, Changsha Medical University

[4] Department of Health Statistics, School of Public Health, Chongqing Medical University, Chongqing

来源：

Computers in Biology and Medicine | 2025年 / 188卷

基金：

中国国家自然科学基金;

关键词：

Bioinformatics; Lower-grade glioma; Molecular subtypes; Neutrophil extracellular traps; qRT-PCR; Tumor microenvironment;

D O I：

10.1016/j.compbiomed.2025.109844

中图分类号：

学科分类号：

摘要：

There is growing evidence linking neutrophil extracellular traps (NETs) to tumor genesis, growth, distant metastasis, and tumor-related thrombosis. However, the roles of NETs-related genes (NETRGs) on LGG prognosis remain unclear. The purpose of this study was to integrate multiple machine learning techniques and experiment validation to develop a reliable NETs-based signature that opens up novel approaches for assessing the prognosis and treatment response of LGG patients. Consensus clustering, k-means clustering and Nonnegative Matrix Factorization was used for the TCGA-LGG dataset and identified two NETs-related subgroups. The prognostic hallmark and nomogram for LGG were developed, which consist of five differentially expressed NETRGs (FPR1, PTAFR, SLC11A1, ICAM1, LTF) based on nine analytic approaches. The ROC curves and calibration curves of our NETRGs signature and nomogram exhibited strong and robust prognosis prediction abilities in both the TCGA-LGG training set and CGGA-325, CGGA-693 validation sets. The prognosis for LGG individuals in the low-risk category was better. The TISCH was used to examine the five NETRGs at the single-cell level. Common immunological checkpoints were expressed at greater levels in high-risk individuals. LGG individuals in the low-risk category posses a higher likelihood of being sensitive to Carmustine and Vincristine, as indicated by the drug sensitivity analysis. The qRT-PCR experiment and immunohistochemistry images confirmed that the expression of FPR1, PTAFR, SLC11A1 and ICAM1 are higher in low-grade oligodendroglioma. The NETRGs signature and nomogram can accurately and conveniently predict the LGG patients’ prognosis, which can facilitate individualized treatment and the improvement of prognosis. © 2025

引用

共 62 条

[1]

Louis D.N., Perry A., Wesseling P., Brat D.J., Cree I.A., Figarella-Branger D., Et al., The 2021 WHO classification of tumors of the central nervous system: a summary, Neuro Oncol., 23, 8, pp. 1231-1251, (2021)

[2]

Schiff D., Van den Bent M., Vogelbaum M.A., Wick W., Miller C.R., Taphoorn M., Et al., Recent developments and future directions in adult lower-grade gliomas: society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus, Neuro Oncol., 21, 7, pp. 837-853, (2019)

[3]

Tom M.C., Cahill D.P., Buckner J.C., Dietrich J., Parsons M.W., Yu J.S., Management for different glioma subtypes: are all low-grade gliomas created equal?, Am Soc Clin Oncol Educ Book, 39, pp. 133-145, (2019)

[4]

Ostrom Q.T., Price M., Neff C., Cioffi G., Waite K.A., Kruchko C., Et al., CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016—2020, Neuro Oncol., 25, pp. iv1-iv99, (2023)

[5]

Powter B., Jeffreys S.A., Sareen H., Cooper A., Brungs D., Po J., Et al., Human TERT promoter mutations as a prognostic biomarker in glioma, J. Cancer Res. Clin. Oncol., 147, 4, pp. 1007-1017, (2021)

[6]

Reifenberger G., Wirsching H.G., Knobbe-Thomsen C.B., Weller M., Advances in the molecular genetics of gliomas - implications for classification and therapy, Nat. Rev. Clin. Oncol., 14, 7, pp. 434-452, (2017)

[7]

Oprita A., Baloi S.C., Staicu G.A., Alexandru O., Tache D.E., Danoiu S., Et al., Updated insights on EGFR signaling pathways in glioma, Int. J. Mol. Sci., 22, 2, (2021)

[8]

Zhang N., Yang F., Zhao P., Jin N., Wu H., Liu T., Et al., MrGPS: an m6A-related gene pair signature to predict the prognosis and immunological impact of glioma patients, Briefings Bioinf., 25, 1, (2023)

[9]

Liu X.P., Jin X., Seyed Ahmadian S., Yang X., Tian S.F., Cai Y.X., Et al., Clinical significance and molecular annotation of cellular morphometric subtypes in lower-grade gliomas discovered by machine learning, Neuro Oncol., 25, 1, pp. 68-81, (2023)

[10]

Wang N., Gao X., Ji H., Ma S., Wu J., Dong J., Et al., Machine learning-based screening of an epithelial-mesenchymal transition-related long non-coding RNA signature reveals lower-grade glioma prognosis and the tumor microenvironment and predicts antitumor therapy response, Front. Mol. Biosci., 9, (2022)

← 1 2 3 4 5 6 7 →